Overview

Substance Misuse To Psychiatric Disorders for Cannabis

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
With the recent availability of vortioxetine, and the surging phenomenon of cannabis misuses amongst young abusers, it is a timely opportunity to conduct an early pharmacotherapy intervention study to offer an evidence-based strategy aiming to stop individuals with cannabis use disorders with depressive or anxiety symptoms, to develop into a more chronic disabling dependence or co-morbid state.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
The University of Hong Kong
Collaborator:
Queen Mary Hospital, Hong Kong
Treatments:
Vortioxetine